Integrated safety analysis of phase 3 studies for investigational microbiome therapeutic, SER-109, in recurrent CDI

Background: Clostridioides difficile infection (CDI) often recurs in patients aged ≥65 years and those with comorbidities. Clinical trials often exclude patients with history of immunosuppression, malignancy, renal insufficiency, or other comorbidities. In a phase 3 trial (ECOSPOR III), SER-109 was...

Descripción completa

Detalles Bibliográficos
Autores principales: Sims, Matthew, Berenson, Charles, Cohen, Stuart, Wang, Elaine, Hohmann, Elizabeth, Nathan, Richard, Odio, Alberto, Cook, Paul, Brady, Kelly, Lombardi, David, Memisoglu, Asli, De, Ananya, Hasson, Brooke, Lashner, Bret, Korman, Louis, Grimard, Doria, Gutierrez, Juan Carlos Moises, McGovern, Barbara, Moltke, Lisa Von
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2023
Materias:
C. difficile
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10594344/
http://dx.doi.org/10.1017/ash.2023.281

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10594344/
http://dx.doi.org/10.1017/ash.2023.281

Ejemplares similares